A carregar...
A pharmacological rationale for improved everolimus dosing in oncology and transplant patients
AIMS: Everolimus is a drug from the class of mammalian target of rapamycin inhibitors used for both immunosuppressant and oncological indications. We postulate that there is room for improvement of dosing, as the optimal immunosuppressive dose in calcineurin‐free regimens is unknown and since the on...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6005589/ https://ncbi.nlm.nih.gov/pubmed/29574974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13591 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|